Anchored in technology licensed from The Johns Hopkins University, Gemstone Biotherapeutics is organized a around commercializing the firm's Extracellular Matrix Replacement (EMR) technology that yields robust skin regeneration in preclinical studies. Previously dba Hydro3Labs LLC and as Chiron Labs LLC, the firm has develped a highly tunable, novel biosynthetic wound healing product that is close to full FDA review. The firm's novel biosynthetic material offers the potential to regeneration of the skin - tissue that comes back without scarring, with restoration of hair follicles and sebaceous glands having the normal structures of healthy, living skin. Intially targeting the dermatology space: acute wound care resulting from abnormal mole removal, skin cancer surgery, and biopsies - situation in which typically return of nornal skin is rare, the manufactured biosynthetic material being developed by Gemstone would address this situation.
